Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

Abstract Background Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used off-label with variable results. The...

Full description

Bibliographic Details
Main Authors: Elisabetta Buscarini, Luisa Maria Botella, Urban Geisthoff, Anette D. Kjeldsen, Hans Jurgen Mager, Fabio Pagella, Patrizia Suppressa, Roberto Zarrabeitia, Sophie Dupuis-Girod, Claire L. Shovlin, on behalf of VASCERN-HHT
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Hereditary hemorrhagic telangiectasia
Bevacizumab
Thalidomide
Adverse event
Bleeding
Arteriovenous malformation
Online Access:http://link.springer.com/article/10.1186/s13023-018-0982-4

Internet

http://link.springer.com/article/10.1186/s13023-018-0982-4

Similar Items